#ASCO22: Following back-to-back TIGIT bombs, Roche offers insight into first PhIII trial fail - Endpoints News
6/6/2022 12:00:00 AM3 years 8 months ago
by Lei Lei Wu
by Lei Lei Wu
Roche’s Genentech suffered two consecutive Phase III fails for tiragolumab, the earliest in a series of anti-TIGIT drugs from Big Pharmas hoping to usher in the next generation of immune checkpoint therapies. Today, the Swiss Pharma unveiled specific data on …
In an ongoing, 18-person study, every single patient that has completed treatment saw their rectal cancer completely disappear. None of them needed chemotherapy, radiation, or surgery — the combinat… [+556 chars]
full article...